(Circulation. 1997;96:2137-2143.)
© 1997 American Heart Association, Inc.
Articles |
Prevention of the Angiographic Progression of Coronary and Vein-Graft Atherosclerosis by Gemfibrozil After Coronary Bypass Surgery in Men With Low Levels of HDL Cholesterol
From the Department of Medicine, Helsinki University Central Hospital (M.H.F., M.S., M.S.N., M-R.T.); Department of Medicine, Oulu University Hospital (H.K., Y.A.K.); and Department of Medicine, Tampere University Hospital (S.M., V.V., A.P.), Finland.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionAppendix 1References |
|---|
Background Studies have shown that treatment of hyperlipidemia, especially lowering of plasma LDL levels, retards the progression of coronary atherosclerosis and prevents clinical cardiovascular events. No such studies have focused on subjects with low levels of HDL cholesterol.
Methods and Results We randomly assigned 395
post–coronary bypass men, who had an HDL
cholesterol concentration 
1.1 mmol/L and LDL
cholesterol 4.5 mmol/L, to receive gemfibrozil 1200
mg/d or placebo. Coronary angiography was performed at baseline
and after, on average, 32 months of therapy. Changes in
coronary dimensions were assessed by computer-assisted
analysis. Average on-trial serum triglyceride
concentrations were 1.69±0.68 and 1.02±0.37, total
cholesterol 5.48±0.68 and 4.83±0.63, LDL
cholesterol 3.84±0.59 and 3.39±0.56, and HDL
cholesterol 0.88±0.15 and 0.98±0.17 mmol/L in the
placebo and gemfibrozil groups, respectively (mean±SD, each
P<.001). The change in per-patient means of average
diameters of native coronary segments was –0.04±0.11 mm
in the placebo group and –0.01±0.10 mm in the gemfibrozil group
(P=.009). The equivalent changes in minimum luminal
diameters of stenoses were –0.09±0.18 and –0.04±0.15
mm, respectively (P=.002). A similar, albeit nonsignificant,
trend toward treatment benefit was found in the predefined primary
study end point, segments unaffected by grafts and those distal to
graft insertions. In aortocoronary bypass grafts, 23 subjects
(14%) assigned to placebo had new lesions in the follow-up angiogram,
compared with 4 subjects (2%) assigned to gemfibrozil
(P<.001).
Conclusions Gemfibrozil therapy retarded the progression of coronary atherosclerosis and the formation of bypass-graft lesions after coronary bypass surgery in men with low HDL cholesterol as their main lipid abnormality.
Key Words: coronary disease • bypass • lipoproteins • angiography • trials
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionAppendix 1References |
|---|
A number of clinical trials have shown benefit from lipid-modifying therapy in patients with established coronary atherosclerosis.1 These studies have used diverse therapeutic regimens, including diet and other lifestyle modifications,2 3 4 combined-drug therapy,5 6 7 8 single-drug therapy,4 9 10 11 12 13 a multifactorial prevention program,14 and partial ileal bypass surgery.15 With one exception,13 all successful secondary-prevention trials so far have lowered LDL cholesterol levels in the groups assigned to active therapy. The Scandinavian Simvastatin Survival Study16 and the CARE trial17 confirmed that lowering LDL cholesterol may be associated with reduced total and cardiovascular mortality and nonfatal cardiac events.
Another common feature in the published secondary-prevention studies is that they have enrolled hyperlipidemic subjects and aimed at reducing the levels of atherogenic lipoproteins, mainly LDL. One study included only subjects with lipid levels regarded as normal, but it did not show benefit from lipid lowering.18
A low plasma HDL level is associated with a high risk of atherosclerosis.19 20 21 Low HDL is a common dyslipidemia among patients with coronary artery disease.22 23 Gemfibrozil, a fibric acid derivative, was found to reduce the incidence of cardiovascular events in the Helsinki Heart Study,24 a primary-prevention trial in middle-aged dyslipidemic men. This beneficial result was associated with a gemfibrozil-induced increment of HDL levels.25 26 The present study, LOCAT, was designed to expand these findings to another population, men who have undergone coronary bypass surgery and who have low HDL cholesterol concentrations as their main lipid abnormality. The study was carried out in three university hospitals in Finland: Helsinki, Oulu, and Tampere. We compared gemfibrozil with placebo therapy in a double-blind, randomized study using end points based on computer-assisted quantitative interpretation of serial coronary angiograms.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionAppendix 1References |
|---|
Patients
Three hundred ninety-five men
70 years old were randomly
assigned in a double-blind fashion to receive either slow-release
gemfibrozil (Lopid SR) 1200 mg/d or a matching placebo. All
patients had previously undergone coronary bypass surgery. They
fulfilled the following lipid criteria at two consecutive screening
visits: HDL cholesterol 1.1 mmol/L (42.5
mg/dL), LDL cholesterol 4.5 mmol/L
(174 mg/dL), and serum triglycerides 4.0
mmol/L (354 mg/dL). In addition, they had blood pressure
160/95 mm Hg; body mass index 30 kg/m2;
left ventricular ejection fraction 
35%; no history of
diabetes and fasting serum glucose concentration <7.8
mmol/L (140 mg/dL); and no conditions requiring therapy
with calcium channel blockers, ACE inhibitors, or
diuretics. Persons who smoked >20 cigarettes/wk were excluded.
Details of the entry criteria and the screening process were described
previously.27 All patients provided written informed consent. The study was approved by the ethics committees of the participating hospitals.
Dietary Counseling
At baseline, all patients received detailed instructions to
maintain a diet containing 30% of energy as fat, with polyunsaturated,
monounsaturated, and saturated fat each
contributing 10%; 50% of energy as carbohydrate, preferably complex
carbohydrates; and <300 mg cholesterol/d.
Coronary Angiography
Native coronary arteries and bypass grafts were imaged
at baseline and at the end of the trial as described
previously.27 28 Briefly, 0.5 mg
nitroglycerin was given sublingually at the beginning
of the procedure and every 20 minutes thereafter to control vasomotor
tone. Angiographic views and other gantry settings were recorded at
baseline and reproduced exactly at the follow-up study. Stringent
quality control of all participating angiography laboratories was
performed before the study and regularly during the study by an
experienced third party.
Cineframes were selected for quantitative computer-assisted analysis in matching views and identical parts of the cardiac cycle, usually in end diastole or in the diastasis period, by projecting the baseline and follow-up films side by side. The images were analyzed with the Cardiovascular Measurement System (Medis)29 by a single trained technical analyst. The accuracy and precision of the angiographic analyses was shown to be comparable to those reported previously by other investigators.28 All angiographic analyses and handling of the data were done by persons blinded to the treatment group and the on-trial lipid values.
Clinic Visits and Laboratory Tests
Patients visited one of the three participating clinical centers
1 month, 3 months, 6 months, and 1 year after randomization;
thereafter, the visit intervals did not exceed 6 months. An exercise
test was performed at baseline and at the time of the follow-up
angiography. Among the patients who underwent both angiograms, 24
subjects (placebo 8, gemfibrozil 16; P=.090) had major
deviations from the protocol, defined as missing at least 30 days of
study medication. These interruptions were due to intolerance of the
study drug in 4 placebo and 10 gemfibrozil subjects, to concomitant
medical conditions in 3 and 4 subjects, and to nonmedical reasons in 1
and 2 subjects, respectively.
Fasting serum triglycerides and cholesterol were measured at each visit with automated enzymatic methods.27 HDL cholesterol was measured in the supernatant after precipitation with phosphotungstic acid and magnesium chloride, and LDL cholesterol was calculated.27 Average values from three prerandomization visits were considered to represent baseline lipid levels; on-trial lipid values were averaged over first-year visits, visits after the first year, and the entire double-blind period. Extensive lipoprotein and other metabolic studies were performed at baseline and after 1 and 2 years of randomized therapy.27 The results of these studies will be reported separately.
End Points and Statistical Analysis
The change from the baseline to the follow-up angiogram in the
ADS and MLD of the stenoses was assessed. Per-patient means of
these variables were calculated in three types of native
coronary segments differing in their relation to bypass grafts
(unaffected, graft-affected [proximal to graft insertions and
hemodynamically related], and graft-dependent [mainly
distal to graft insertions])27 and in saphenous vein
bypass grafts. Per-patient means were also calculated for ADS and MLD
values in all native segments and in the "primary" segments,
comprising unaffected and graft-dependent segments. Changes in the
primary segments were predefined as the main end point of the
study.27
New lesions were defined as stenoses in the follow-up angiogram causing at least 20% diameter reduction (or milder if clearly present by visual analysis) that were not present in the baseline angiogram. New lesions suggested by the computer-assisted analysis were verified by visual inspection of the paired angiograms.
The mean per-patient changes in ADS and MLD were compared in the
randomized groups by ANOVA, adjusted for study center, the baseline
value of the dependent variable, and the time interval between the
baseline and follow-up angiograms. The number of patients showing new
lesions was compared by the 
2 test. Differences
in patient characteristics at baseline were evaluated by ANOVA or the
2 test, as appropriate. Baseline and on-trial
lipid levels were compared by ANOVA; triglycerides were
transformed to their natural logarithms before statistical tests. A
two-tailed value of P<.05 was considered statistically
significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionAppendix 1References |
|---|
Baseline Characteristics
One hundred ninety-eight subjects were randomized to receive placebo and 197 subjects, gemfibrozil. The groups were well balanced at baseline (Table 1
). Of the 395 randomized
subjects, 372 (94%) underwent the follow-up angiogram. The 187
subjects in the placebo group had 4.1±1.2 (mean±SD) distal bypass
anastomoses, and the 185 subjects assigned to gemfibrozil had 4.0±1.3
anastomoses, indicating similar severity of coronary artery
disease before bypass surgery. Reasons for missing the follow-up
angiogram were concomitant illnesses (placebo 4, gemfibrozil 4),
withdrawal of informed consent because of intolerance of the study drug
(3 and 5), technical vascular access problems (2 and 1), and
unwillingness (2 and 2 subjects, respectively). The 23 subjects who did
not complete the trial had baseline characteristics similar to those of
the subjects who underwent both angiograms (data not shown).
|
Changes in Lipid Levels
Fig 1 shows the baseline and
on-trial lipid levels in the randomized groups. Among the patients in
the gemfibrozil group who completed the study, triglyceride
levels were reduced on average by 36%, total and LDL
cholesterol levels were reduced by 5.5% and 4.5%,
respectively, and HDL cholesterol levels were increased by
21% from baseline to mean on-trial levels. In the placebo group, the
corresponding changes were triglycerides +4.6%, total
cholesterol +5.1%, LDL cholesterol +5.3%, and
HDL cholesterol +7.0%. Average on-trial lipid levels in
the placebo group were triglycerides, 1.69±0.68
mmol/L (154±62 mg/dL); cholesterol,
5.48±0.68 mmol/L (211±26 mg/dL); LDL
cholesterol, 3.84±0.59 mmol/L (148±23
mg/dL); and HDL cholesterol, 0.88±0.15
mmol/L (34±6 mg/dL); and in the gemfibrozil group,
1.02±0.37 mmol/L (92±34 mg/dL); 4.83±0.63
mmol/L (186±24 mg/dL); 3.39±0.56 mmol/L
(130±21 mg/dL); and 0.98±0.17 mmol/L (38±7
mg/dL), respectively (mean±SD). All between-group differences
in on-trial lipid levels and in the changes from baseline were highly
significant (P<.001).
|
Angiographic End Points
Time intervals between the two angiograms were 32±2 months for
the placebo group (range, 27 to 41 months) and 32±3 months for the
gemfibrozil group (range, 13 to 40 months). As shown in Table 2, when coronary segments were
analyzed separately according to their relation to bypass
grafts, diffuse progression of coronary
atherosclerosis, expressed as the per-patient mean
reduction in the ADS, was significantly milder in the gemfibrozil group
than in the placebo group in segments unaffected by grafts and in
graft-affected segments. By contrast, there was no significant change
in the ADS values of the graft-dependent segments either in the placebo
group (P=.518, paired t test) or in the
gemfibrozil group (P=.903) and therefore no difference
between the randomized groups. In the primary segments (unaffected and
graft-dependent segments combined), there was a trend in favor of
gemfibrozil that was not statistically significant. When all types of
native coronary segments (unaffected, graft-affected, and
graft-dependent) were taken into account, there was significantly less
progression in the gemfibrozil group compared with placebo. In these
segments, the difference in mean changes of ADS was 0.03 mm (95%
CI, 0.004 to 0.046 mm).
|
Table 2
also shows that progression of focal coronary
atherosclerosis, assessed as changes in the MLD of
stenotic lesions, was reduced in patients randomized to
gemfibrozil compared with those in the placebo group, although this
difference was not statistically significant for the primary segments.
In all native segments combined, the difference in mean changes of MLD
was 0.05 mm (95% CI, 0.018 to 0.087 mm). Again, this overall
difference was accounted for by the unaffected and the graft-affected
segments, because there was on average virtually no progression in
lesions located in the graft-dependent segments. Expressed as average
per-patient change in percent diameter stenosis, lesion
progression was milder in gemfibrozil than in placebo patients
(1.2±6.4 versus 2.1±6.6, 1.6±7.4 versus 2.4±8.9, 0.8±8.5 versus
2.4±9.4, and 0.3±7.2 versus 1.3±7.7 percentage points in primary,
unaffected, graft-affected, and graft-dependent segments,
respectively), but these differences were not statistically
significant.
The appearance of new lesions was not significantly affected by gemfibrozil therapy in unaffected segments (18 patients with one or more new lesions in the placebo group and 15 in the gemfibrozil group) or in graft-dependent segments (12 and 9, respectively). Thus, one of the predefined principal end points, appearance of new lesions in primary segments, did not show a significant difference between the groups (P=.578). In the graft-affected segments, however, 18 patients assigned to placebo had new lesions, compared with 6 of those assigned to gemfibrozil (P=.008).
We observed a marked reduction by active treatment in the number of new
lesions in the venous aortocoronary bypass grafts (placebo, 23
of 161 patients with analyzable grafts; gemfibrozil, 4 of 165;
P<.001). The mean diameter stenosis of these
lesions was 37±13% and 32±12% in the placebo and gemfibrozil
groups, respectively (P>.2). As expected in patients
studied on average 
2 years after bypass surgery, only 45% of the
patients with analyzable vein grafts had stenotic graft lesions
in their baseline angiograms (placebo, 73 and gemfibrozil, 74
patients). Thus, the study was underpowered to detect differences in
changes of preexisting graft lesions; accordingly, none were found
(data not shown).
Nine patients in the placebo group and 4 in the gemfibrozil group
experienced a vein graft occlusion during the study
(P=.185). Because altered flow conditions in graft-affected
segments might influence diameters of these segments after graft
closure, we performed ANOVAs of ADS and MLD changes in these segments
after exclusion of patients with graft occlusions. The results were
similar to those presented in Table 2 (P=.005 and
P=.008, respectively).
Clinical and Adverse Events
There were no deaths during the trial. Only 7 patients in each
group had a major coronary event (myocardial infarction or a
revascularization procedure). As in the baseline
study, a minority of the patients had any signs of ischemia in
the end-of-study exercise test (placebo, 66 and gemfibrozil, 63
subjects). Likewise, only 28 and 39 subjects assigned to placebo and
gemfibrozil, respectively, reported any angina symptoms during the week
preceding follow-up angiography.
Cancer was diagnosed during the study in 7 placebo patients and in 3 gemfibrozil patients. Eleven subjects assigned to placebo and 22 subjects assigned to gemfibrozil were found to have new or worsening diseases of the gastrointestinal tract (odds ratio, 2.137; 95% CI, 1.007 to 4.536; P=.044). This difference was due to upper gastrointestinal diseases (esophagitis, Helicobacter pylori gastritis, or ulcer; placebo, 4 and gemfibrozil, 11) and to gastrointestinal hemorrhages (2 and 6, respectively). Significant liver enzyme elevations were reported in 9 gemfibrozil patients and in none of the placebo patients (P=.002); all were reversible after discontinuation of the drug.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionAppendix 1References |
|---|
The results of the present study indicate that therapy with gemfibrozil, a fibric acid derivative, retards angiographic progression of coronary and vein-graft atherosclerosis in a group of post–coronary bypass men selected primarily on the basis of low HDL cholesterol levels at baseline. It is important to note that the patients were also selected to have relatively low LDL cholesterol levels (
4.5
mmol/L) and that patients with hypertension not controlled by
ß-blocker monotherapy, with diabetes mellitus, and with poor left
ventricular function were excluded. Thus, the results
should not be generalized to other types of coronary
patients. So far, only one angiographic secondary-prevention trial has shown benefit from therapy with a fibric acid derivative.13 BECAIT found retarded progression of coronary atherosclerosis in a group of hyperlipidemic young male survivors of myocardial infarction randomized to receive bezafibrate compared with placebo. Although that study was smaller than the present one, it also showed significantly fewer clinical cardiovascular events in the bezafibrate group. Our trial was not designed to study the effect of gemfibrozil on clinical end points. On the contrary, we selected a group of men who had recently undergone a successful bypass operation and who were therefore expected to have a good prognosis for several years.30 Taken together, BECAIT13 and our study with gemfibrozil suggest a role for fibric acid derivatives in the secondary prevention of coronary artery disease. Two large, ongoing fibrate trials with clinical end points,31 32 when completed, will further help to define the role of this class of compounds in the management of coronary patients.
Fig 2 compares angiographic outcomes in
four studies that used the Cardiovascular Measurement
System for quantitative angiographic analyses. Although there
were differences in average or median per-patient MLD scores at
baseline, lipid levels of the study populations, and study durations,
the angiographic results were markedly similar: in each study there was
a significant reduction in the progression of coronary
atherosclerosis. Two of the studies,
CCAIT10 and REGRESS,12 used statin therapy in
patients with mild to moderate
hypercholesterolemia, and the main lipid effect
in these studies was reduction of LDL cholesterol. The two
other studies, BECAIT13 and the present study (LOCAT),
used a fibrate that mainly reduced triglyceride levels and
raised HDL levels. A logical conclusion of these observations is that
therapy of dyslipidemia, tailored to suit the lipoprotein
phenotype of each patient, is beneficial in the retardation of
atherosclerosis progression.
|
CLAS5 6 showed less progression and more regression of
coronary atherosclerosis in a group of
middle-aged post–coronary bypass men randomized to receive
niacin and colestipol compared with placebo. When the changes in the
native coronary arteries were studied in greater detail, the
CLAS investigators found that much of the global benefit from active
therapy was confined to the segments proximal to graft
insertions.33 Although the importance of these bypassed
proximal segments for myocardial blood flow may often be limited,
clinical follow-up of the CLAS patients indicated that angiographic
change in that study was a significant predictor of future clinical
events,34 suggesting that disease progression in proximal
segments serves as a valid surrogate end point for clinical events. As
in CLAS, we found less progression and fewer new lesions in the
proximal segments during gemfibrozil than during placebo therapy.
Importantly, we also noted a significant treatment benefit in the
nonbypassed coronary segments. By contrast, disease progression
over 2.5 years in graft-dependent segments was minimal as assessed by
computer-derived end points, in agreement with earlier studies based on
visual interpretation of angiograms.35 Accordingly, no
treatment effect could be found in these segments, which diluted the
benefit observed in the primary end point of our study. Indeed, the
treatment benefit was directly related to the propensity for
progression in a given segment type: greatest in the graft-affected
segments, moderate in nonbypassed segments, and nonexistent in distal
segments (Fig 3).
|
Also in accordance with CLAS, we found less disease progression, manifesting as fewer new lesions, in the venous aortocoronary bypass grafts in the active-therapy group. In fact, only 2% of our actively treated patients had new graft lesions, compared with 14% of the placebo-treated patients. Thus, our data support the conclusions of CLAS, namely that active treatment of dyslipidemia after bypass surgery retards the progression of atherosclerosis both in native coronary arteries and in bypass grafts.
Although in the present study, on-trial LDL cholesterol values were significantly lower in subjects assigned to gemfibrozil than in the placebo group, the decrease in LDL cholesterol in our study (–4.5%) was smaller than in most previous studies.2 3 4 5 6 7 8 9 10 11 12 14 15 16 17 In BECAIT,13 a treatment benefit was found, although there was no change in average LDL cholesterol levels. These two fibrate trials showed, as expected, a major decrease in serum triglyceride concentrations and an elevation in HDL cholesterol. Subgroup analyses in CLAS36 and in CCAIT10 suggested that triglyceride-rich lipoproteins and HDL assume an important role in the progression of atherosclerosis after elevated LDL levels have been lowered. In support of these data, the CARE study17 recently showed that LDL lowering was not beneficial in patients with baseline LDL cholesterol concentrations <3.2 mmol/L (125 mg/dL), in contrast to those with higher LDL levels, suggesting that other lipoprotein classes or nonlipid atherogenic insults may determine the progression of atherosclerosis in this subgroup of coronary patients. The results of the present study support the hypothesis that in patients with low HDL but normal or only mildly elevated LDL cholesterol levels, reduction of the atherogenic remnants of triglyceride-rich lipoproteins37 38 and enhancement of reverse cholesterol transport,39 40 by increasing levels of the antiatherogenic HDL,41 retard the progression of coronary artery disease.
|
Selected Abbreviations and Acronyms |
|---|
|
|
Appendix 1 |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionAppendix 1References |
|---|
LOCAT Investigators and Staff
Principal Investigator: M. Heikki Frick, MD.
Steering Committee: M. Heikki Frick, MD, chairman (University of Helsinki); Vesa Manninen, MD (University of Helsinki); Y. Antero Kesäniemi, MD (University of Oulu); Amos Pasternack, MD (University of Tampere); James W. Nawrocki, MS (Parke-Davis, Ann Arbor, MI).
Safety Committee: Juhani Heikkilä, MD, chairman; Olli P. Heinonen, MD; Jussi K. Huttunen, MD.
Core Quantitative Angiography Laboratory: Mikko Syvänne, MD; Markku S. Nieminen, MD; Mervi Pietilä, QCA technician.
Core Lipid Laboratory: Marja-Riitta Taskinen, MD. Technicians: Hannele Hilden, Leena Lehikoinen, Ritva Marjanen, Helinä Perttunen-Nio, Sirpa Rannikko, Sirkka-Liisa Runeberg.
Clinical Investigators: Helsinki, Mikko Syvänne, MD. Oulu, Heikki Kauma, MD. Tampere, Silja Majahalme, MD; Vesa Virtanen, MD.
Senior Investigators: Oulu, Markku Savolainen, MD. Tampere, Kari Pietilä, MD.
Coronary Angiographers: Helsinki, Markku S. Nieminen, MD; Kari S. Virtanen, MD. Oulu, Markku Ikäheimo, MD; Heikki Huikuri, MD; Juhani Airaksinen, MD; Juhani Koistinen, MD. Tampere, Kari Niemelä, MD; Taisto Talvensaari, MD; Olli Anttonen, MD; Kaj Groundstroem, MD; Vesa Virtanen, MD.
Clinical Staff: Helsinki, Anita Leppämäki, RN. Oulu, Liisa Laine, RN; Leena Virkkala, RN. Tampere, Heidi Hällström, RN.
Study Secretaries: Päivi Närvä, Sirpa Koskela.
Dietitian: Kaisa Ketonen, RD.
Parke-Davis Monitor: Elina Jalkanen, CRA.
|
Acknowledgments |
|---|
This study was supported by grants from Parke-Davis, a division of Warner Lambert; the Finnish Foundation for Cardiovascular Research; the Aarne Koskelo Foundation; and the Finnish Society of Angiology.
|
Footnotes |
|---|
Reprint requests to Prof M.H. Frick, Department of Medicine, Division of Cardiology, Helsinki University Central Hospital, Haartmaninkatu 4, FIN-00290 Helsinki, Finland.
1 The institutions and investigators participating in the Lopid Coronary Angiography Trial are listed in the "Appendix." 
Received December 23, 1996; revision received May 12, 1997; accepted May 20, 1997.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionAppendix 1References |
|---|
1. Gotto AM Jr. Lipid lowering, regression, and coronary events: a review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, seventh council meeting. Circulation. 1995;92:646-656.
2. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, McLanahan SM, Kirkeeide RL, Brand RJ, Gould KL. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990;336:129-133.[Medline] [Order article via Infotrieve]
3.
Schuler G, Hambrecht R, Schlierf G, Niebauer J, Hauer
K, Neumann J, Hoberg E, Drinkmann A, Bacher F, Grunze M, Kübler
W. Regular physical exercise and low-fat diet: effects on
progression of coronary artery disease.
Circulation. 1992;86:1-11.
4. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltard DJ, Smith LDR, Mann JI, Swan AV. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet. 1992;339:563-569.[Medline] [Order article via Infotrieve]
5.
Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME,
Azen SP, Cashin-Hemphill L. Beneficial effects of combined
colestipol-niacin therapy on coronary
atherosclerosis and coronary venous bypass
grafts. JAMA. 1987;257:3233-3240.
6.
Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME,
Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin
on coronary atherosclerosis: a 4-year
follow-up. JAMA. 1990;264:3013-3017.
7. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin J-T, Kaplan C, Zhao X-Q, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.[Abstract]
8.
Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC,
Havel RJ. Regression of coronary
atherosclerosis during treatment of familial
hypercholesterolemia with combined drug
regimens. JAMA. 1990;264:3007-3012.
9.
Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ,
Cashin-Hemphill L, Hodis HN, DeBoer LWV, Mahrer PR, Masteller MJ,
Vailas LI, Alaupovic P, Hirsch LJ, and the MARS Research Group.
Coronary angiographic changes with lovastatin
therapy: the Monitored Atherosclerosis Regression Study
(MARS). Ann Intern Med. 1993;119:969-976.
10.
Waters D, Higginson L, Gladstone P, Kimball B, Le May
M, Boccuzzi SJ, Lespérance J, the CCAIT Study Group. Effects of
monotherapy with an HMG-CoA reductase inhibitor on the
progression of coronary atherosclerosis as
assessed by serial quantitative arteriography: the Canadian
Coronary Atherosclerosis Intervention Trial.
Circulation. 1994;89:959-968.
11. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344:633-638.[Medline] [Order article via Infotrieve]
12.
Jukema JW, Bruschke AVG, van Boven AJ, Reiber JHC, Bal
ET, Zwinderman AH, Jansen H, Boerma GJM, van Rappard FM, Lie KI, on
behalf of the REGRESS Study Group. Effects of lipid lowering by
pravastatin on progression and regression of
coronary artery disease in symptomatic men with
normal to moderately elevated serum cholesterol levels: the
Regression Growth Evaluation Statin Study (REGRESS).
Circulation. 1995;91:2528-2540.
13. Ericsson C-G, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996;347:849-853.[Medline] [Order article via Infotrieve]
14.
Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF,
Superko HR, Williams PT, Johnstone IM, Champagne MA, Krauss RM,
Farquhar JW. Effects of intensive multiple risk factor reduction
on coronary atherosclerosis and clinical
cardiac events in men and women with coronary artery disease:
the Stanford Coronary Risk Intervention Project
(SCRIP). Circulation. 1994;89:975-990.
15. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD Jr, Sawin HS Jr, Campos CT, Hansen BJ, Tuna N, Karnegis JN, Sanmarco ME, Amplatz K, Castaneda-Zuniga WR, Hunter DW, Bissett JK, Weber FJ, Stevenson JW, Leon AS, Chalmers TC, and the POSCH Group. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990;323:946-955.[Abstract]
16. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.[Medline] [Order article via Infotrieve]
17.
Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford
JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR,
Braunwald E. The effect of pravastatin on
coronary events after myocardial infarction in patients with
average cholesterol levels. N Engl
J Med. 1996;335:1001-1009.
18. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH, for the Harvard Atherosclerosis Reversibility Project (HARP) Group. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Lancet. 1994;344:1182-1186.[Medline] [Order article via Infotrieve]
19. Nikkilä E. Studies on the lipid-protein relationships in normal and pathologic sera and the effect of heparin on serum lipoproteins. Scand J Clin Lab Invest. 1953;5(suppl 8):1-101.
20. Gordon DJ, Rifkind BM. High-density lipoprotein: the clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316.[Medline] [Order article via Infotrieve]
21.
Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD,
Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler A.
High-density lipoprotein cholesterol and
cardiovascular disease: four prospective American
studies. Circulation. 1989;79:8-15.
22. Miller M, Kwiterovich PO Jr. Isolated low HDL-cholesterol as an important risk factor for coronary heart disease. Eur Heart J. 1990;11(suppl H):9-14.
23. Miller M, Mead LA, Kwiterovich PO Jr, Pearson TA. Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease. Am J Cardiol. 1990;65:1-5.[Medline] [Order article via Infotrieve]
24. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.[Abstract]
25.
Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP,
Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P,
Mäenpää H, Mälkönen M,
Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M,
Sjöblom T, Nikkilä EA. Lipid alterations and decline
in the incidence of coronary heart disease in the Helsinki
Heart Study. JAMA. 1988;260:641-651.
26.
Manninen V, Tenkanen L, Koskinen P, Huttunen JK,
Mänttäri M, Heinonen OP, Frick MH. Joint effects of
serum triglyceride and LDL cholesterol
concentrations on coronary heart disease risk in the Helsinki
Heart Study: implications for treatment.
Circulation. 1992;85:37-45.
27. Syvänne M, Taskinen M-R, Nieminen MS, Manninen V, Kesäniemi YA, Pasternack A, Nawrocki JW, Haber H, Frick MH. A study to determine the response of coronary atherosclerosis to raising low HDL cholesterol with a fibric-acid derivative in men after coronary bypass surgery: the rationale, design, and baseline characteristics of the LOCAT study. Control Clin Trials. 1997;18:93-119.[Medline] [Order article via Infotrieve]
28. Syvänne M, Nieminen MS, Frick MH. Accuracy and precision of quantitative arteriography in the evaluation of coronary artery disease after coronary bypass surgery: a validation study. Int J Vasc Imaging. 1994;10:243-252.
29. Reiber JHC, van der Zwet PMJ, von Land CD, Koning G, van Meurs B, Buis B, van Voorthuisen AE. Quantitative coronary arteriography: equipment and technical requirements. In: Reiber JHC, Serruys PW, eds. Advances in Quantitative Coronary Arteriography. Dordrecht, Netherlands: Kluwer Academic Publishers; 1993:75-111.
30. Van Brussel BL, Plokker T, Ernst SMPG, Ernst NM, Knaepen PJJ, Koomen EM, Tijssen JGP, Vermeulen FEE, Voors AA. Venous coronary artery bypass surgery: a 15-year follow-up study. Circulation. 1993;88:87-92.
31. Rubins HB, Robins SJ, Iwane MK, Boden WE, Elam MB, Fye CL, Gordon DJ, Schaefer EJ, Schectman G, Wittes JT. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol. 1993;71:45-52.[Medline] [Order article via Infotrieve]
32. Goldbourt U, Behar S, Reicher-Reiss H, Agmon J, Kaplinsky E, Graff E, Kishon Y, Caspi A, Weisbort J, Mandelzweig L, Abinader E, Aharon L, Braun S, David D, Flich M, Friedman Y, Kristal N, Leil N, Markiewicz W, Marmor A, Palant A, Pelled B, Rabinowitz B, Reisin L, Roguin N, Rosenfeld T, Schlesinger Z, Sclarovsky S, Sherf L, Tzivoni D, Zahavi I, Zion M, Brunner D, for the Bezafibrate Infarction Prevention Study Group. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol. 1993;71:909-915.[Medline] [Order article via Infotrieve]
33.
Blankenhorn DH, Selzer RH, Mack WJ, Crawford DW, Pogoda
J, Lee PL, Shircore AM, Azen SP. Evaluation of colestipol/niacin
therapy with computer-derived coronary end point measures: a
comparison of different measures of treatment effect.
Circulation. 1992;86:1701-1709.
34.
Azen SP, Mack WJ, Cashin-Hemphill L, LaBree L, Shircore
AM, Selzer RH, Blankenhorn DH. Progression of coronary
artery disease predicts clinical coronary events: long-term
follow-up from the Cholesterol Lowering
Atherosclerosis Study. Circulation. 1996;93:34-41.
35. Frick MH, Valle M, Harjola P-T. Progression of coronary artery disease in randomized medical and surgical patients over a 5-year angiographic follow-up. Am J Cardiol. 1983;52:681-685.[Medline] [Order article via Infotrieve]
36.
Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen
SP. Prediction of angiographic change in native human
coronary arteries and aortocoronary bypass grafts:
lipid and nonlipid factors. Circulation. 1990;81:470-476.
37.
Austin MA. Plasma triglyceride and
coronary heart disease. Arterioscler Thromb. 1991;11:2-14.
38. Miesenböck G, Patsch JR. Postprandial hyperlipidemia: the search for the atherogenic lipoprotein. Curr Opin Lipidol. 1992;3:196-201.
39. Glomset JA. The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res. 1968;9:155-167.[Abstract]
40. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995;36:211-228.[Abstract]
41. Tall AR. Plasma high density lipoproteins: metabolism and relationship to atherogenesis. J Clin Invest. 1990;86:379-384.
This article has been cited by other articles:
 |
|
 |
|
  E. Gongora and T. M. Sundt III Myocardial Revascularization with Cardiopulmonary Bypass Card. Surg. Adult, January 1, 2008; 3(2008): 599 - 632. [Full Text]
|
|
|
|
 |
|
 I. M. Singh, M. H. Shishehbor, and B. J. Ansell High-Density Lipoprotein as a Therapeutic Target: A Systematic Review JAMA, August 15, 2007; 298(7): 786 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Garg and V. Simha Update on Dyslipidemia J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1581 - 1589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Freeman, A. L. Drake, L. F. Heilig, M. Graber, K. McNealy, L. M. Schilling, and R. P. Dellavalle Statins, Fibrates, and Melanoma Risk: a Systematic Review and Meta-analysis. J Natl Cancer Inst, November 1, 2006; 98(21): 1538 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Gilde, J.-C. Fruchart, and B. Staels Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A24 - A32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Wierzbicki Diabetic dyslipidaemia: the triad Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F30 - F33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zambon, P. Gervois, P. Pauletto, J.-C. Fruchart, and B. Staels Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR-{alpha} Activators: Clinical and Experimental Evidence Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 977 - 986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M J. Chapman Review: Fibrates: therapeutic review The British Journal of Diabetes & Vascular Disease, January 1, 2006; 6(1): 11 - 19. [Abstract] [PDF]
|
|
|
|
|
|
L. F Van Gaal, F. Peiffer, and D. Ballaux Reducing cardiovascular risk in patients with type 2 diabetes: the potential contribution of nicotinic acid The British Journal of Diabetes & Vascular Disease, November 1, 2005; 5(6): 344 - 350. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Lan and D. L. Silver Fenofibrate Induces a Novel Degradation Pathway for Scavenger Receptor B-I Independent of PDZK1 J. Biol. Chem., June 17, 2005; 280(24): 23390 - 23396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.J. Barter Antiatherogenic Properties of Fibrates Arterioscler. Thromb. Vasc. Biol., June 1, 2005; 25(6): 1095 - 1096. [Full Text] [PDF]
|
|
|
|
|
|
S. N. Chen, C. M. Ballantyne, A. M. Gotto Jr, Y. Tan, J. T. Willerson, and A. J. Marian A Common PCSK9 Haplotype, Encompassing the E670G Coding Single Nucleotide Polymorphism, Is a Novel Genetic Marker for Plasma Low-Density Lipoprotein Cholesterol Levels and Severity of Coronary Atherosclerosis J. Am. Coll. Cardiol., May 17, 2005; 45(10): 1611 - 1619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Cariou, J.-C. Fruchart, and B. Staels Review: Vascular protective effects of peroxisome proliferator-activated receptor agonists The British Journal of Diabetes & Vascular Disease, May 1, 2005; 5(3): 126 - 132. [Abstract] [PDF]
|
|
|
|
|
|
K. Okrainec, R. Platt, L. Pilote, and M. J. Eisenberg Cardiac medical therapy in patients after undergoing coronary artery bypass graft surgery: A review of randomized controlled trials J. Am. Coll. Cardiol., January 18, 2005; 45(2): 177 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Birjmohun, B. A. Hutten, J. J.P. Kastelein, and E. S.G. Stroes Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials J. Am. Coll. Cardiol., January 18, 2005; 45(2): 185 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Whitney, R. A. Krasuski, B. E. Personius, J. E. Michalek, A. M. Maranian, M. W. Kolasa, E. Monick, B. G. Brown, and A. M. Gotto Jr. A Randomized Trial of a Strategy for Increasing High-Density Lipoprotein Cholesterol Levels: Effects on Progression of Coronary Heart Disease and Clinical Events Ann Intern Med, January 18, 2005; 142(2): 95 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Okapcova and D. Gabor The Levels of Soluble Adhesion Molecules in Diabetic and Nondiabetic Patients with Combined Hyperlipoproteinemia and the Effect of Ciprofibrate Therapy Angiology, November 1, 2004; 55(6): 629 - 639. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Marx, H. Duez, J.-C. Fruchart, and B. Staels Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells Circ. Res., May 14, 2004; 94(9): 1168 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Talmud, S. Martin, M.-R. Taskinen, M. H. Frick, M. S. Nieminen, Y. A. Kesaniemi, A. Pasternack, S. E. Humphries, and M. Syvanne APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study J. Lipid Res., April 1, 2004; 45(4): 750 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ou, Z. Ou, D. W. Jones, S. Holzhauer, O. A. Hatoum, A. W. Ackerman, D. W. Weihrauch, D. D. Gutterman, K. Guice, K. T. Oldham, et al. L-4F, an Apolipoprotein A-1 Mimetic, Dramatically Improves Vasodilation in Hypercholesterolemia and Sickle Cell Disease Circulation, May 13, 2003; 107(18): 2337 - 2341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Barter Review: Reconsidering the value of fibrates: lessons from the trials The British Journal of Diabetes & Vascular Disease, May 1, 2003; 3(3): 162 - 167. [Abstract] [PDF]
|
|
|
|
|
|
P. J. Talmud, S. Martin, G. Steiner, D. M. Flavell, D. B. Whitehouse, S. Nagl, R. Jackson, M.-R. Taskinen, M. H. Frick, M. S. Nieminen, et al. Progression of Atherosclerosis Is Associated With Variation in the {alpha}1-Antitrypsin Gene Arterioscler. Thromb. Vasc. Biol., April 1, 2003; 23(4): 644 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Ou, J. Ou, A. W. Ackerman, K. T. Oldham, and K. A. Pritchard Jr L-4F, an Apolipoprotein A-1 Mimetic, Restores Nitric Oxide and Superoxide Anion Balance in Low-Density Lipoprotein-Treated Endothelial Cells Circulation, March 25, 2003; 107(11): 1520 - 1524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ma, M. Cilingiroglu, J. D. Otvos, C. M. Ballantyne, A. J. Marian, and L. Chan Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism PNAS, March 4, 2003; 100(5): 2748 - 2753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mardones, A. Pilon, M. Bouly, D. Duran, T. Nishimoto, H. Arai, K. F. Kozarsky, M. Altayo, J. F. Miquel, G. Luc, et al. Fibrates Down-regulate Hepatic Scavenger Receptor Class B Type I Protein Expression in Mice J. Biol. Chem., February 28, 2003; 278(10): 7884 - 7890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Pineda Torra, T. Claudel, C. Duval, V. Kosykh, J.-C. Fruchart, and B. Staels Bile Acids Induce the Expression of the Human Peroxisome Proliferator-Activated Receptor {alpha} Gene via Activation of the Farnesoid X Receptor Mol. Endocrinol., February 1, 2003; 17(2): 259 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
References Circulation, December 17, 2002; 106(25): 3373 - 3421. [Full Text]
|
|
|
|
|
|
I. Pineda Torra, Y. Jamshidi, D. M. Flavell, J.-C. Fruchart, and B. Staels Characterization of the Human PPAR{alpha} Promoter: Identification of a Functional Nuclear Receptor Response Element Mol. Endocrinol., May 1, 2002; 16(5): 1013 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Barbier, I. P. Torra, Y. Duguay, C. Blanquart, J.-C. Fruchart, C. Glineur, and B. Staels Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors in Lipid Metabolism and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., May 1, 2002; 22(5): 717 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Calabresi, M. Gomaraschi, B. Villa, L. Omoboni, C. Dmitrieff, and G. Franceschini Elevated Soluble Cellular Adhesion Molecules in Subjects With Low HDL-Cholesterol Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 656 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Freedman Antioxidant versus Lipid-Altering Therapy -- Some Answers, More Questions N. Engl. J. Med., November 29, 2001; 345(22): 1636 - 1637. [Full Text] [PDF]
|
|
|
|
|
|
P. K. Shah, S. Kaul, J. Nilsson, and B. Cercek Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part I Circulation, November 6, 2001; 104(19): 2376 - 2383. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Amarenco Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction Neurology, September 1, 2001; 57(90002): S35 - 44. [Abstract] [Full Text]
|
|
|
|
|
|
S. R. Kapadia, S. E. Nissen, K. M. Ziada, G. Rincon, T. D. Crowe, N. Boparai, J. B. Young, and E. M. Tuzcu Impact of lipid abnormalities in development and progression of transplant coronary disease: a serial intravascular ultrasound study J. Am. Coll. Cardiol., July 1, 2001; 38(1): 206 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Bloomfield Rubins, J. Davenport, V. Babikian, L. M. Brass, D. Collins, L. Wexler, S. Wagner, V. Papademetriou, G. Rutan, and S. J. Robins Reduction in Stroke With Gemfibrozil in Men With Coronary Heart Disease and Low HDL Cholesterol : The Veterans Affairs HDL Intervention Trial (VA-HIT) Circulation, June 12, 2001; 103(23): 2828 - 2833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Elangbam, R. D. Tyler, and R. M. Lightfoot Peroxisome Proliferator-activated Receptors in Atherosclerosis and Inflammation--An Update Toxicol Pathol, February 1, 2001; 29(2): 224 - 231. [Abstract] [PDF]
|
|
|
|
 |
|
 R. D. Santos, L. I. Ventura, A. C. Sposito, R. Schreiber, J. A.F. Ramires, and R. C. Maranhao The effects of gemfibrozil upon the metabolism of chylomicron-like emulsions in patients with endogenous hypertriglyceridemia Cardiovasc Res, February 1, 2001; 49(2): 456 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Artery Disease : The Bezafibrate Infarction Prevention (BIP) Study Circulation, July 4, 2000; 102(1): 21 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Guyton, M. A. Blazing, J. Hagar, M. L. Kashyap, R. H. Knopp, J. M. McKenney, D. T. Nash, S. D. Nash, and for the Niaspan-Gemfibrozil Study Group Extended-Release Niacin vs Gemfibrozil for the Treatment of Low Levels of High-Density Lipoprotein Cholesterol Arch Intern Med, April 24, 2000; 160(8): 1177 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Garcia-Moll, F. Coccolo, D. Cole, and J. C. Kaski Serum neopterin and complex stenosis morphology in patients with unstable angina J. Am. Coll. Cardiol., March 15, 2000; 35(4): 956 - 962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Delerive, K. De Bosscher, S. Besnard, W. Vanden Berghe, J. M. Peters, F. J. Gonzalez, J.-C. Fruchart, A. Tedgui, G. Haegeman, and B. Staels Peroxisome Proliferator-activated Receptor alpha Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-kappa B and AP-1 J. Biol. Chem., November 5, 1999; 274(45): 32048 - 32054. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Knopp Drug Treatment of Lipid Disorders N. Engl. J. Med., August 12, 1999; 341(7): 498 - 511. [Full Text] [PDF]
|
|
|
|
|
|
H. V. Huikuri, V. Jokinen, M. Syvanne, M. S. Nieminen, K. E. J. Airaksinen, M. J. Ikaheimo, J. M. Koistinen, H. Kauma, A. Y. Kesaniemi, S. Majahalme, et al. Heart Rate Variability and Progression of Coronary Atherosclerosis Arterioscler. Thromb. Vasc. Biol., August 1, 1999; 19(8): 1979 - 1985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Campeau, D. B. Hunninghake, G. L. Knatterud, C. W. White, M. Domanski, S. A. Forman, J. S. Forrester, N. L. Geller, F. L. Gobel, J. A. Herd, et al. Aggressive Cholesterol Lowering Delays Saphenous Vein Graft Atherosclerosis in Women, the Elderly, and Patients With Associated Risk Factors : NHLBI Post Coronary Artery Bypass Graft Clinical Trial Circulation, June 29, 1999; 99(25): 3241 - 3247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. N. Hodis Triglyceride-Rich Lipoprotein Remnant Particles and Risk of Atherosclerosis Circulation, June 8, 1999; 99(22): 2852 - 2854. [Full Text] [PDF]
|
|
|
|
|
|
C. R. Harper and T. A. Jacobson New Perspectives on the Management of Low Levels of High-Density Lipoprotein Cholesterol Arch Intern Med, May 24, 1999; 159(10): 1049 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Ballantyne, J. A. Herd, L. L. Ferlic, J. K. Dunn, J. A. Farmer, P. H. Jones, J. R. Schein, and A. M. Gotto Jr Influence of Low HDL on Progression of Coronary Artery Disease and Response to Fluvastatin Therapy Circulation, February 16, 1999; 99(6): 736 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Syvanne, M. S. Nieminen, M. H. Frick, H. Kauma, S. Majahalme, V. Virtanen, Y. A. Kesaniemi, A. Pasternack, C. Ehnholm, and M.-R. Taskinen Associations Between Lipoproteins and the Progression of Coronary and Vein-Graft Atherosclerosis in a Controlled Trial With Gemfibrozil in Men With Low Baseline Levels of HDL Cholesterol Circulation, November 10, 1998; 98(19): 1993 - 1999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Staels, J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J.-C. Fruchart Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism Circulation, November 10, 1998; 98(19): 2088 - 2093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Chinetti, S. Griglio, M. Antonucci, I. P. Torra, P. Delerive, Z. Majd, J.-C. Fruchart, J. Chapman, J. Najib, and B. Staels Activation of Proliferator-activated Receptors alpha and gamma Induces Apoptosis of Human Monocyte-derived Macrophages J. Biol. Chem., October 2, 1998; 273(40): 25573 - 25580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Havel Benefits of Fibrate Drugs in Coronary Heart Disease Patients With Normal Cholesterol Levels Circulation, October 7, 1997; 96(7): 2113 - 2114. [Full Text]
|
|
|
|
|
|
P. Gervois, N. Vu-Dac, R. Kleemann, M. Kockx, G. Dubois, B. Laine, V. Kosykh, J.-C. Fruchart, T. Kooistra, and B. Staels Negative Regulation of Human Fibrinogen Gene Expression by Peroxisome Proliferator-activated Receptor alpha Agonists via Inhibition of CCAAT Box/Enhancer-binding Protein beta J. Biol. Chem., August 31, 2001; 276(36): 33471 - 33477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Calabresi, M. Gomaraschi, B. Villa, L. Omoboni, C. Dmitrieff, and G. Franceschini Elevated Soluble Cellular Adhesion Molecules in Subjects With Low HDL-Cholesterol Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 656 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Flavell, Y. Jamshidi, E. Hawe, I. Pineda Torra, M.-R. Taskinen, M. H. Frick, M. S. Nieminen, Y. A. Kesaniemi, A. Pasternack, B. Staels, et al. Peroxisome Proliferator-Activated Receptor {alpha} Gene Variants Influence Progression of Coronary Atherosclerosis and Risk of Coronary Artery Disease Circulation, March 26, 2002; 105(12): 1440 - 1445. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||